FY2025 Earnings Estimate for TNYA Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised its FY2025 earnings estimate for Tenaya Therapeutics to a loss of ($0.71) per share, slightly down from the previous estimate of ($0.70), while the consensus estimate is a loss of ($1.35) per share.
• Tenaya Therapeutics reported a quarterly loss of ($0.14) EPS, exceeding the consensus estimate of ($0.20) by $0.06.
• Despite the earnings adjustment, Tenaya Therapeutics has had a favorable reception from analysts, with a majority rating it as a "buy" and an average price target of $6.25.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Leerink Partnrs cut their FY2025 EPS estimates for shares of Tenaya Therapeutics in a research report issued on Wednesday, August 6th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($0.71) for the year, down from their previous estimate of ($0.70). The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics' Q4 2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.67) EPS.

Several other research firms have also issued reports on TNYA. HC Wainwright restated a "buy" rating and issued a $5.00 target price on shares of Tenaya Therapeutics in a report on Friday, April 25th. Wall Street Zen raised shares of Tenaya Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $9.00 price target on shares of Tenaya Therapeutics in a research note on Thursday, August 7th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $6.25.

Tenaya Therapeutics Price Performance

Shares of Tenaya Therapeutics stock traded up $0.01 during trading on Monday, hitting $0.87. The stock had a trading volume of 1,325,889 shares, compared to its average volume of 2,764,337. The firm's fifty day simple moving average is $0.68 and its 200-day simple moving average is $0.66. The stock has a market cap of $141.46 million, a PE ratio of -0.90 and a beta of 3.01. Tenaya Therapeutics has a 12 month low of $0.36 and a 12 month high of $4.01.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.06.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Cerity Partners LLC increased its position in Tenaya Therapeutics by 403.5% during the 2nd quarter. Cerity Partners LLC now owns 110,336 shares of the company's stock valued at $67,000 after purchasing an additional 88,424 shares during the period. Marshall Wace LLP acquired a new stake in Tenaya Therapeutics in the 2nd quarter worth approximately $90,000. Savant Capital LLC acquired a new stake in Tenaya Therapeutics in the 2nd quarter worth approximately $52,000. CWM LLC lifted its stake in Tenaya Therapeutics by 25.2% during the 2nd quarter. CWM LLC now owns 90,087 shares of the company's stock valued at $55,000 after acquiring an additional 18,142 shares during the period. Finally, Woodline Partners LP lifted its stake in Tenaya Therapeutics by 30,563.2% during the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock valued at $3,373,000 after acquiring an additional 5,896,873 shares during the period. Hedge funds and other institutional investors own 90.54% of the company's stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.